Dr. Reddy's Laboratories Limited (RDY) Financial Statements

Executive TeamFinancials
Shareholders

Dr. Reddy's Laboratories financial statements at a glance

Dr. Reddy's Laboratories reported revenue of 335.93 billion INR for fiscal year 2026 (ended March 31, 2026), up 3.2% from fiscal year 2025. Net income was 41.96 billion INR, a net margin of 12.5%, and diluted earnings per share were 50.35 INR.

At the end of fiscal year 2026 it had total assets of 579.35 billion INR, total liabilities of 198.89 billion INR and shareholders' equity of 377.06 billion INR, with cash and short-term investments of 87.81 billion INR and total debt of 77.34 billion INR.

Its operations brought in 56.74 billion INR of cash; capital spending was 38.41 billion INR, leaving free cash flow of 18.33 billion INR.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in INR; latest fiscal year ended March 31, 2026.

RDY logo

Dr. Reddy's Laboratories Limited

RDYIndia
Healthcare
INR (Local)

Income Statement

Annual • INR

Total Revenue
335.93B
Prev Year: 325.54B
YoY: +3.2%
Operating Revenue
335.93B
Prev Year: 325.54B
YoY: +3.2%
Normalized EBITDA
81.77B
Prev Year: 91.97B
YoY: -11.1%
Tax Rate for Calcs
0.229
Prev Year: 0.25
YoY: -8.4%
Tax Effect of Unusual Items
-805.73M
Prev Year: 1.18B
YoY: -168.5%
Other Income Expense
10.20B
Prev Year: 4.92B
YoY: +107.2%
Other Non-operating Income (expense)
13.58B
Total Operating Income as Reported
-
Prev Year: 71.84B
Special Income Charges
-3.52B
Prev Year: -171.00M
YoY: -1957.3%
Impairment of Capital Assets
3.52B
Prev Year: 1.69B
YoY: +107.8%
Equity in Earnings of Affiliates
134.00M
Prev Year: 217.00M
YoY: -38.2%
Gain on Sale of Property, Plant and Equipment
-
Prev Year: 1.52B
Depreciation Amortization Depletion
20.59B
Depreciation and amortization
20.59B
Salaries and Wages
59.91B
Gain on Sale of Securities
-
Prev Year: 4.88B
Cost of Revenue
122.39B
Prev Year: 135.11B
YoY: -9.4%
Gross Profit
213.54B
Prev Year: 190.43B
YoY: +12.1%
Operating Expense
166.08B
Prev Year: 118.41B
YoY: +40.3%
Selling General and Administrative
59.91B
Prev Year: 93.87B
YoY: -36.2%
General and Administrative Expense
59.91B
Other Operating Expenses
85.58B
Prev Year: -2.84B
YoY: +3117.6%
Research and Development
-
Prev Year: 27.38B
Operating Income
47.47B
Prev Year: 72.01B
YoY: -34.1%
Net Non Operating Interest Income Expense
-3.74B
Prev Year: -152.00M
YoY: -2359.2%
Non-operating Interest Expense
3.74B
Prev Year: 2.83B
YoY: +32.1%
Non-operating Interest Income
-
Prev Year: 2.68B
Pre-tax Income
53.93B
Prev Year: 76.78B
YoY: -29.8%
Provision for Income Taxes
12.35B
Prev Year: 19.54B
YoY: -36.8%
Net Income Common Stockholders
41.96B
Prev Year: 56.54B
YoY: -25.8%
Net Income
41.96B
Prev Year: 56.54B
YoY: -25.8%
Net Income Including Non-Controlling Interests
41.58B
Prev Year: 57.24B
YoY: -27.4%
Net Income from Continuing Operations
41.58B
Prev Year: 57.24B
YoY: -27.4%
Noncontrolling Interests
384.00M
Prev Year: -701.00M
YoY: +154.8%
Diluted NI Available to Com Stockholders
41.96B
Prev Year: 56.54B
YoY: -25.8%
Basic EPS
50.41
Prev Year: 67.89
YoY: -25.7%
Diluted EPS
50.35
Prev Year: 67.79
YoY: -25.7%
Weighted Average Shares (basic)
832.37M
Prev Year: 832.98M
YoY: -0.1%
Weighted Average Shares (diluted)
833.37M
Prev Year: 834.21M
YoY: -0.1%
Total Expenses
288.47B
Prev Year: 253.52B
YoY: +13.8%
Net Income from Continuing and Discontinued Operation
41.96B
Prev Year: 56.54B
YoY: -25.8%
Normalized Income
44.67B
Prev Year: 53.02B
YoY: -15.7%
Interest Expense
3.74B
Prev Year: 2.83B
YoY: +32.1%
Interest Income
-
Prev Year: 2.68B
Net Interest Income
-3.74B
Prev Year: -152.00M
YoY: -2359.2%
EBIT
57.66B
Prev Year: 79.61B
YoY: -27.6%
EBITDA
78.25B
Prev Year: 96.67B
YoY: -19.1%
Reconciled Cost of Revenue
122.39B
Prev Year: 135.11B
YoY: -9.4%
Reconciled Depreciation
20.59B
Prev Year: 17.06B
YoY: +20.7%
Net Income from Continuing Operation Net Minority Interest
41.96B
Prev Year: 56.54B
YoY: -25.8%
Total Unusual Items Excluding Goodwill
-3.52B
Prev Year: 4.71B
YoY: -174.8%
Total Unusual Items
-3.52B
Prev Year: 4.71B
YoY: -174.8%
Values in INR

Dr. Reddy's Laboratories key figures by fiscal year

FY2026FY2025FY2024FY2023FY2022
Revenue335.9B INR325.5B INR279.2B INR245.9B INR214.4B INR
Gross profit213.5B INR190.4B INR163.6B INR139.3B INR113.8B INR
Operating income47.5B INR72.0B INR65.3B INR59.1B INR35.9B INR
Net income42.0B INR56.5B INR55.7B INR45.1B INR23.6B INR
Diluted EPS50.35 INR67.79 INR66.80 INR54.17 INR28.34 INR
Total assets579.3B INR493.0B INR387.5B INR321.9B INR292.8B INR
Total liabilities198.9B INR155.8B INR107.0B INR90.9B INR102.3B INR
Shareholders' equity377.1B INR333.4B INR280.6B INR231.0B INR190.5B INR
Cash and short-term investments87.8B INR57.9B INR81.5B INR61.8B INR44.4B INR
Total debt77.3B INR46.8B INR20.0B INR13.5B INR33.8B INR
Operating cash flow56.7B INR46.4B INR45.4B INR58.9B INR28.1B INR
Capital spending38.4B INR34.4B INR27.4B INR18.9B INR19.0B INR
Free cash flow18.3B INR12.0B INR18.0B INR40.0B INR9.1B INR

In INR. Fiscal years as reported by the company; statements on this page go back to fiscal year 2015.

Questions and answers

What was Dr. Reddy's Laboratories's revenue in fiscal year 2026?

335.93 billion INR, up 3.2% from 325.54 billion INR in fiscal year 2025.

How much profit does Dr. Reddy's Laboratories make?

Dr. Reddy's Laboratories reported net income of 41.96 billion INR for fiscal year 2026 (12.5% of revenue); operating income was 47.47 billion INR.

How much cash and debt does Dr. Reddy's Laboratories have?

At the end of fiscal year 2026: cash and short-term investments of 87.81 billion INR and total debt of 77.34 billion INR.

What is Dr. Reddy's Laboratories's free cash flow?

18.33 billion INR in fiscal year 2026 (operating cash flow of 56.74 billion INR minus capital spending of 38.41 billion INR).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube